Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from PFE

1 Big Pharma Dividend Stock to Snag While It's Still Cheap

Pfizer's stock presents a compelling investment opportunity, trading at an attractive valuation with a high dividend yield, as the company makes promising progress on its oral obesity drug, danuglipron, in a market dominated by injectable treatments.

Barchart

Patriots for Europe? Viktor Orbán’s new EU group is another hollow victory for the far right

Marine Le Pen’s RN and Hungary’s Fidesz have joined forces. But Europe’s far right is fractured and Orbán isolated, says political scientist Cas Mudde

The Guardian - UK

3 Value Stocks to Buy and Hold for Passive Income

Amid market volatility, three value stocks - American International Group (AIG), Pfizer (PFE), and Schlumberger (SLB) - emerge as potential long-term investments for passive income, offering attractive valuations, solid dividends, and growth prospects for investors.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Ultra High-Yield Dividend Stocks to Pounce On at Every Dip

These dividend stocks have consistently paid dividends with yields over 6%.

Barchart

Is Pfizer Stock Underperforming the Nasdaq?

Pfizer has recently lagged the Nasdaq Composite, but analysts are optimistic about the stock’s prospects.

Barchart

Should You Buy This S&P 500 Stock with a Dividend Yield of Nearly 6%?

With a dividend yield of nearly 6%, pharma giant Pfizer is among the highest-yielding S&P 500 stocks. While the stock's price action has been disappointing like most other high-dividend stocks, it looks worth a bet given the tepid valuations.

Barchart

A journey of global expansion and resilience in freight forwarding

As we celebrate the launch of the E2E International 100, we spoke to Adam Collins, Managing Director of PFE Express, a freight forwarding and logistics company, to gain further insights into his international business journey, discovering some of the challenges faced in the industry, and what strategies were implemented to help…

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Dividend Stability and Growth in Pharma: Pfizer (PFE) vs. Bristol-Myers Squibb (BMY)

The pharma sector is primed for solid growth owing to technological advancements, growing healthcare needs, and a rise in chronic diseases. Given this backdrop, let’s analyze the fundamentals of pharmaceutical stocks Pfizer (PFE) and Bristol-Myers Squibb (BMY) to determine which of these stocks offer better dividend stability and growth. Read…

StockNews.com

2 Covered Call Ideas on Pfizer Stock

Income investors tend to gravitate towards covered calls, and blue-chip high yielding stocks are a great place to start.

Barchart

Eli Lilly (LLY) or Pfizer (PFE): Which Stock Can Surge From Earnings?

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

StockNews.com

5 Underperforming Stocks That Look Ready to Rebound, According to Goldman

Analysts at Goldman Sachs think these 5 underperforming stocks could be poised to outperform, thanks to a healthy valuation discount and expected EPS growth.

Barchart

2 Defensive Stocks to Buy Now as 'Higher For Longer' Woes Rattle Markets

U.S. stocks fell yesterday as the 10-year Treasury yield rose above 4.5% amid sticky inflation. As markets turn volatile, Pfizer and Apple look like two defensive names worth considering.

Barchart

Down 32% in a Year, Should Investors Buy the Dip in Pfizer Stock?

Down more than 30% in a year, pharmaceutical company Pfizer trades near its 52-week lows. Is this the right time to buy in the dip?

Barchart

2 Cheap Dividend Stocks to Buy This March and Hold for the Long Term

While the S&P 500 Index's dividend yield is just about half of its long-term averages, Ford and Pfizer are two dividend-paying stocks that offer healthy yields. Plus, their cheap valuations mean that there is a reasonable probability of upside over the next couple of years.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Pfizer (PFE) vs. Johnson & Johnson (JNJ) - Analyzing Pharma Stocks for Upside Potential

The pharmaceutical industry is expected to witness robust growth over the coming years due to growing healthcare needs and advancements in technology. Given this positive backdrop, let’s analyze the upside potential of pharma stocks Pfizer (PFE) and Johnson & Johnson (JNJ).

StockNews.com

Pharma Stocks Analysis: Grab, Hold, or Sell?

Despite economic pressures and intensified competition, government incentives and drug innovations are fueling growth in the pharma sector. So, let us delve into the analysis of leading pharma stocks Bristol-Myers Squibb (BMY), Collegium Pharmaceutical (COLL), Pfizer (PFE), and Vaxcyte (PCVX), assessing whether to Grab, Hold, or Sell the stocks amid…

Barchart

Pfizer Stock 2025 Forecast: Will PFE Go Up Long Term?

Pfizer stock is trading at price levels last seen in 2016. The 2025 forecast for PFE stock looks positive, though, and it should go up over the medium to long term.

StockNews.com

Pharma Stock Analysis: Buy, Hold, or Sell These 4?

Amid rising global medical needs, an aging population, and technological advancements, the pharmaceutical industry is expected to witness robust growth over the coming years. Given this positive backdrop, let’s analyze the investment prospects of pharma stocks Madrigal (MDGL), Pfizer (PFE), Astellas (ALPMY), and Novo Nordisk (NVO). Read on.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Pfizer (PFE): Pre-Earnings Strategies

Pfizer (PFE) is facing hurdles due to weakened demand for its products and pipeline diversification challenges. Nevertheless, the company exhibits long-term potential through strategic acquisitions. Given this scenario, what course of action should be considered ahead of the upcoming earnings release? Read more to find out.

Barchart

Where Will Pfizer Stock Be in 1 Year?

PFE is a beaten-down healthcare stock that trades at a discount to consensus price target estimates. Is Pfizer stock a good buy right now?

StockNews.com

Pfizer (PFE) 2024 Preview: What to Expect From the Pharma Stock?

As Pfizer (PFE) navigates a post-pandemic world with a shifting focus away from COVID-related products, what should investors expect from this pharma giant? Let’s look at its financial metrics to know more….

Barchart

I’ve Got 5 Stocks and 5 DTEs: Which Call Should I Buy?

Wednesday’s unusual options activity had multiple stocks with two or more calls expiring on the same day. Five stocks caught my interest. Only one of the calls is worth buying.

StockNews.com

Pfizer Inc. (PFE) vs. Taro Pharmaceutical (TARO) - Betting on Which Pharma Stock Will Have Q4 Dominance

The pharmaceutical industry’s prospects are driven by the rising occurrence of chronic diseases coupled with the adoption of cutting-edge technology. In this context, which company among the two major industry players, Pfizer Inc. (PFE) and Taro Pharmaceutical (TARO) are going to dominate the fourth quarter? Let’s find out….

Barchart

How to Buy PFE For a 7% Discount, or Achieve a 16% Annual Return

Selling cash secured puts on stocks an investor is happy to take ownership of is a great way to generate some extra income.

StockNews.com

Can Pfizer (PFE) and AbbVie (ABBV) Cure Your Portfolio's Ailments?

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Amid this, let’s analyze the fundamentals of AbbVie (ABBV) and Pfizer (PFE) to determine whether these stocks are worth buying now.

1 … 4 5 6 7

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.